PHOENIX SENOLYTIX
LIVE

Serial Number

98919084

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Dec 23, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PHOENIX SENOLYTIX Trademark

Serial Number: 98919084

PHOENIX SENOLYTIX is a trademark filed by SENOTHERAPEUTIX, Inc. on December 23, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc.

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

December 23, 2024

Registration Date

Not Registered

Goods & Services

Anti-aging therapy; Medical services, namely, anti-aging services; Medical testing services, namely, biologic age scoring; Medical testing services in the nature of statistical scoring to determine a biologic age score of a patient; Medical services; Medical services, namely, anti-aging services; Medical services, namely, prevention and treatment of age-related disorders; Medical research services; Medical research services, namely, anti-aging services; Medical research services, namely, prevention and treatment of age-related disorders; Medical advisory services; Medical advisory services, namely, anti-aging services; Medical advisory services, namely, prevention and treatment of age-related disorders; Medical testing services; Medical testing services, namely, anti-aging services; Medical testing services, namely, prevention and treatment of age-related disorders; Medical services in the field of anti-aging; Medical services in the field of senescent cells; Medical services in the field of age-related disorders; Medical testing services, namely, biopsy services; Medical testing services, namely, biopsy services related to biologic age; Medical testing services, namely, biopsy services related to biological age scoring; Biopsy services related to determining a number or percentage of senescent cells; Laboratory services being medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, laboratory services related to biologic age; Laboratory services related to biological age scoring, namely medical analysis services for diagnostic and treatment purposes provided by medical laboratories; Medical analysis services for diagnostic and treatment purposes provided by medical laboratories, namely, laboratory services related to determining a number or percentage of senescent cells; Non-invasive medical testing; Non-invasive medical testing related to biologic age; Non-invasive medical testing related to biological age scoring; Non-invasive medical testing related to determining a number or percentage of senescent cells; Medical care, namely, prevention of radiation damage; Medical care, namely, treatment of radiation damage; Medical care, namely, prevention of radiation related diseases; Medical care, namely, treatment of radiation related diseases; Medical care, namely, treatment of obesity; Providing weight loss program services in the nature of weight loss regimens; Medical care, namely, treatment of obesity in combination with other drugs

Development of pharmaceutical preparations and medicines; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Testing, inspection, research, and development of pharmaceutical preparations for age therapy and gene therapy; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Gene therapy research; Gene therapy research related to anti-aging; Gene therapy research related to cancer; Gene therapy related to prevention and treatment of radiation damage and radiation related diseases; Gene therapy related to treatment of obesity; Gene therapy related to weight loss regimens; Gene therapy related to treatment of obesity in combination with other drugs

Pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Gene therapy-based pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders

Filing History

TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 29, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 29, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 29, 2026 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Oct 28, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Oct 28, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jul 29, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jul 29, 2025 CNRT
ASSIGNED TO EXAMINER
Jun 9, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
May 29, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 29, 2025 NWOS
NEW APPLICATION ENTERED
Dec 23, 2024 NWAP